Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/14/2026

1. JPM
2. IBM
3. BAC
4. SPY
5. WFC
6. ERAS
7. SPRO
8. TREX
9. AAPL
10. GS

Go back to Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
Novavax, Inc. (NASDAQ: NVAX) Delayed: 8.91 --0 (-0%)
Previous Close $8.91    52 Week High $9.23 
Open $8.91    52 Week Low $1.16 
Day High $8.91    P/E N/A 
Day Low $8.91    EPS $-0.30 
Volume 11,171       

Novavax, Inc. (NASDAQ: NVAX) Delayed: 8.91 --0 (-0%)
Previous Close $8.91    52 Week High $9.23 
Open $8.91    52 Week Low $1.16 
Day High $8.91    P/E N/A 
Day Low $8.91    EPS $-0.30 
Volume 11,171